阿斯利康在2023年11月与祐森健恒达成授权合作，获得彼时临床前阶段的靶向kras g12d突变的小分子候选药物ua022项目的全球独家授权，这可能正是本次 ...

智通财经APP获悉，1月15日，中国国家药监局药品审评中心(CDE)官网最新公示，阿斯利康(AZN.US)1类新药AZD0022获得临床试验默示 ...

经济观察网讯 1月15日，中国国家药监局药品审评中心（CDE）官网最新公示，阿斯利康1类新药AZD0022获得临床试验默示许可，拟开发治疗携带KRAS G12D ...

智通财经APP获悉，1月15日，中国国家药监局药品审评中心(CDE)官网最新公示，阿斯利康(AZN.US)1类新药AZD0022获得临床试验默示许可，拟开发治疗携带KRAS ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

That is ASP3082, a novel protein degrader that targets mutated KRAS G12D and follows in the footsteps of Amgen’s KRAS inhibitor Lumakras (sotorasib), which became the first drug in the class to ...